- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05413200
Investigation of the Effect of Oral Isotretinoin on Skin Thickness and Elasticity in Patients With Atrophic Acne Scar
Investigation of the Effect of Oral Isotretinoin on Clinical Severity, Skin Thickness, and Elasticity in Patients With Moderate to Severe Acne Vulgaris and Atrophic Acne Scar by Shear-Wave Elastography
Acne scar is a common complication of acne vulgaris (AV). Early and effective treatment of AV has a crucial role in managing both acne and acne scarring. Oral isotretinoin (OI) is a widely preferred agent in treating moderate and severe AV worldwide. It has been shown that topical retinoids can also be effective in the treatment of atrophic acne scars. However, there is no study in the literature evaluating the effectiveness of OI protocol on atrophic scars with objective data. With the developing sonoelastography technology in recent years, a quantitative, objective, and reliable examination of the elasticity of the skin and subcutaneous tissue can be provided. In this study, for a detailed and objective evaluation of the effects of OI on atrophic acne scars, we investigate the AV severity, atrophic scar grade, scar size (SS), dermis and subcutaneous tissue thickness (STT), and changes in scar and subcutaneous tissue elastic modulus (EM) in moderate and severe AV patients with atrophic acne scars by clinical observation and SWE.
Materials and Methods: It was designed as a single-center, prospective and observational study. Ethics committee approval was obtained. Thirty patients who applied to the Istanbul Training and Research Hospital, Dermatology Department, between November 2021 and January 2022 diagnosed with moderate and severe AV accompanied by atrophic acne scars were included in the study. Demographic characteristics of the patients were recorded. We started the OI with a standard dose regime. On days 0 and 90 of treatment, each patient's AV and scar severity; were evaluated with the global acne grading system (GAGS) and the Goodman and Baron Qualitative Global Scar Rating System (GSRS). On the same days, the dermal thickness (DT), STT, SS, scar, and subcutaneous tissue EM on the right and left cheeks were measured by the same experienced radiologist with SWE. Appropriate statistical methods analyzed the results.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34098
- Istanbul Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being over 18 years old
- Being under 65 years old
- Moderate to severe acne vulgaris with atrophic acne scars
- Absence of keloidal or hypertrophic scars
- Planning the use of oral isotretinoin in the treatment
- No additional disease
- Not smoking
- Consent to participate in the study and treatment
Exclusion Criteria:
- Using isotretinoin in the last 1 year
- Using topical or systemic medication in addition to oral isotretinoin for the treatment of acne vulgaris
- Having a keloidal or hypertrophic scar
- Being in pregnancy and lactation period
- To plan a pregnancy or are unable to adapt to contraception
- Known chronic diseases; skin cancer and other cancers, uncontrolled such as diabetes, hepatic failure/dysfunction, renal failure/dysfunction, neuromuscular diseases, autoimmune connective tissue diseases, hematological diseases, malabsorption diseases, inflammatory bowel diseases, pseudotumor cerebri, psychiatric diseases, and alcoholism.
- Severe hypercholesterolemia (>250 mg/dL), hypertriglyceridemia (> 500 mg/dL)
- Elevated liver function tests (ALT, AST, GGT, ALP) exceeding 3 times the upper limit
- Creatine kinase elevation exceeding 5 times the upper limit
- Using regular medication for another known disease
- To smoke
- A dermatological pathology other than facial acne vulgaris. (seborrheic dermatitis, rosacea, perioral dermatitis, herpes infection, impetigo, cutaneous lupus erythematosus, solar keratosis)
- Using Vitamin A
- Those who have or will receive a blood transfusion (during treatment or within 1 month after treatment)
- Hypersensitivity to the drug's preservatives
- Unrealistic expectations from treatment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients
Patients diagnosed with moderate and severe AV accompanied by atrophic acne scars
|
oral isotretinoin with a standard dose regime for 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline atrophic acne scar severity at 90 days
Time Frame: Day 0-90
|
Change from baseline Goodman and Baron Qualitative Global Scar Rating System (first grade: grade 1, last grade: grade 4. Scar severity increases with increasing grade) at 90 days
|
Day 0-90
|
Change from baseline skin thickness at 90 days
Time Frame: Day 0-90
|
Change from baseline dermal and subcutaneous tissue thickness at 90 days
|
Day 0-90
|
Change from baseline skin elasticity at 90 days
Time Frame: Day 0-90
|
Change from baseline scar and subcutaneous tissue elasticity at 90 days
|
Day 0-90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline acne vulgaris severity at 90 days
Time Frame: Day 0-90
|
Change from baseline Global Acne Grading System (minimum score:0, maximum score: 44, severity increases with increasing score) at 90 days
|
Day 0-90
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 98
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
-
Assiut UniversityCompleted
Clinical Trials on Isotretinoin
-
University of North CarolinaCompleted
-
Cipher Pharmaceuticals Inc.CompletedSevere Nodular AcneUnited States, Canada
-
GlaxoSmithKlineCompleted
-
Mostafa BahaaRecruiting
-
National Institute of Arthritis and Musculoskeletal...Completed
-
Centro Dermatológico Dr. Ladislao de la PascuaNot yet recruiting
-
Kayseri Education and Research HospitalKayseri Erciyes University Faculty of MedicineCompletedAdverse Effects of Medical Drugs
-
SciClone PharmaceuticalsNot yet recruiting
-
Laboratoires Bailleul-BiorgaQuanta MedicalCompletedPapular-pustular Rosacea
-
Shanghai Dermatology HospitalRenJi Hospital; Huadong HospitalUnknown